JP2020533969A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533969A5
JP2020533969A5 JP2020511428A JP2020511428A JP2020533969A5 JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5 JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5
Authority
JP
Japan
Prior art keywords
vector
foxp3
cell
lentiviral
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533969A (ja
JP7290288B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047586 external-priority patent/WO2019040655A1/en
Publication of JP2020533969A publication Critical patent/JP2020533969A/ja
Publication of JP2020533969A5 publication Critical patent/JP2020533969A5/ja
Application granted granted Critical
Publication of JP7290288B2 publication Critical patent/JP7290288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511428A 2017-08-22 2018-08-22 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター Active JP7290288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548891P 2017-08-22 2017-08-22
US62/548,891 2017-08-22
PCT/US2018/047586 WO2019040655A1 (en) 2017-08-22 2018-08-22 LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES

Publications (3)

Publication Number Publication Date
JP2020533969A JP2020533969A (ja) 2020-11-26
JP2020533969A5 true JP2020533969A5 (enExample) 2021-09-30
JP7290288B2 JP7290288B2 (ja) 2023-06-13

Family

ID=65439627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511428A Active JP7290288B2 (ja) 2017-08-22 2018-08-22 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター

Country Status (5)

Country Link
US (2) US12060566B2 (enExample)
EP (1) EP3672617A4 (enExample)
JP (1) JP7290288B2 (enExample)
KR (1) KR102780121B1 (enExample)
WO (1) WO2019040655A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
WO2019040655A1 (en) * 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
JP7575949B2 (ja) * 2018-04-27 2024-10-31 シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート 遺伝子編集t細胞におけるヒトfoxp3の発現
SG11202007878UA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Expression of foxp3 in edited cd34+ cells
WO2020216807A1 (en) * 2019-04-23 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing or restoring immune tolerance
EP3980035A4 (en) * 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
EP4410965A4 (en) * 2021-09-27 2025-09-24 Univ Kyoto T LYMPHOCYTE PRODUCTION PROCESS
JPWO2023149555A1 (enExample) * 2022-02-04 2023-08-10
EP4497822A4 (en) * 2022-03-23 2026-03-18 Univ Kyoto PROCESS FOR THE PRODUCTION OF REGULATORY T LYMPHOCYTES
CN120112629A (zh) * 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
CN122382014A (zh) * 2026-06-17 2026-07-14 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 抗鸡Foxp3单克隆抗体、分泌该单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
JP2004208548A (ja) 2002-12-27 2004-07-29 Institute Of Physical & Chemical Research 免疫反応の抗原特異的抑制
US8158596B2 (en) * 2007-05-11 2012-04-17 The Regents Of The University Of Michigan Materials and methods for FOXP3 tumor suppression
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014121840A1 (en) * 2013-02-07 2014-08-14 Medizinische Hochschule Hannover Induced dendritic cells and uses thereof
GB201318347D0 (en) * 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES

Similar Documents

Publication Publication Date Title
Wolff et al. Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years
Vannucci et al. Viral vectors: a look back and ahead on gene transfer technology
Morizono et al. Multilineage cells from adipose tissue as gene delivery vehicles
JP7290288B2 (ja) 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でfoxp3を発現するレンチウイルスベクター
RU2014117201A (ru) ЛЕНТИВИРУСНЫЕ ВЕКТОРЫ, ПСЕВДОТИПИРОВАННЫЕ МУТАНТНЫМИ BaEV
Galimi et al. Opportunities for the use of lentiviral vectors in human gene therapy
JP2020010684A5 (enExample)
WO2009013324A9 (en) Vector particles for targeting cd34+ cells
WO2016039933A1 (en) Lentiviral vector for treating hemoglobin disorders
Freitas et al. Protection is not always a good thing: the immune system’s impact on gene therapy
Lundstrom Gene therapy applications of viral vectors
Bell Jr et al. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors
JP2023544633A (ja) 治療における使用のためのrag1の置き換え
Curran et al. Nonprimate lentiviral vectors
Bergmann et al. Progress and problems with viral vectors for delivery of talens
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
Miyake et al. Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene expression using a recombinant human immunodeficiency virus vector
MIYAKE et al. Two-step gene transfer using an adenoviral vector carrying the CD4 gene and human immunodeficiency viral vectors
WO2023038055A1 (ja) レトロウイルスベクター製造用の核酸
CN116635523A (zh) 用于疗法中的rag1的替代物
Dalberto et al. Mesenchymal stem cells as a platform for gene therapy protocols
Shunchang et al. Expression of truncated dystrophin cDNAs mediated by a lentiviral vector
Counsell et al. 527. Exploiting Retroviral Recombination for the Delivery of Full-Length Dystrophin cDNA
JP2024538769A (ja) Rag1遺伝子における突然変異を修正するのに有用なポリヌクレオチド
US20230040417A1 (en) Defective interfering particles